The Chronic Gout Market to Exhibit Growth at a Considerable CAGR During the Study Period (2019–2032), Assesses DelveInsight

Nevada (Las Vegas), United States, DelveInsight’s “Chronic Gout – Market Insight, Epidemiology and Market Forecast – 2032” report provides current treatment practices, emerging drugs, Chronic Gout market share of the individual therapies, current and forecasted Chronic Gout market size from 2019 to 2032 segmented by seven major markets. The report also offers current Chronic Gout therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Chronic Gout market.

Chronic Gout Overview
Gout is a chronic disease characterized by monosodium urate (MSU) crystal deposition. Gout is frequently characterized by an acute, self-limiting inflammatory monoarthritis of the lower limb joints. Chronic Gout is characterized by long-term joint inflammation that causes joint pain at rest and during activity. Hyperuricemia is one of the most common Chronic Gout causes. Higher serum urate levels are linked to a higher risk of gout flare-ups, as well as more frequent flare-ups over time.

The most common symptom of Chronic Gout is severe joint pain, which is followed by discomfort, inflammation, and redness. A definitive Chronic Gout diagnosis requires laboratory confirmation of synovial fluid MSU in the setting of acute inflammatory arthritis. As a result, a systematic review comparing the accuracy of tests used to diagnose Chronic Gout to synovial fluid UA, such as physical findings, serum UA, ultrasound (US), plain radiography, and dual-energy computed tomography (DECT), can be used to inform clinical decision-making for patients and providers, as well as improve the quality of care for gout patients in the primary and acute care setting.

Chronic Gout Epidemiological Insights
The Chronic Gout epidemiology section provides insights about the historical and current Chronic Gout patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Chronic Gout market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted Chronic Gout epidemiology scenario in the 7MM covering the United States, EU4 countries (Germany, Spain, Italy, France), the United Kingdom, and Japan from 2019 to 2032.

Chronic Gout Treatment Market
The major Chronic Gout therapies on the market are aimed at providing timely relief of pain and disability caused by intense inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs) like colchicine are frequently used as the first line of treatment for Chronic Gout. When NSAIDs and colchicine are contraindicated, glucocorticoids or corticotropin are used instead.

Aside from these medications, several others are used to treat chronic gout. The FDA has approved drugs for the treatment of Chronic Gout, including Febuxostat, KRYSTEXXA (pegloticase injection), Topiroxostat (FYX-051), and Xanthine oxidase inhibitors (XOIs).

Promising Therapies in the Chronic Gout Pipeline
• ABP 671
• AR-882
• TMX-049
• Pegadricase-SVP
• SAP 001

Discover more about Chronic Gout therapies in the pipeline @ Chronic Gout Drugs

Leading Companies Working in the Chronic Gout Market
• Teijin Pharma
• Horizon Therapeutics
• Sanwa Kagaku Kenkyusho Co. Ltd.
• Jiangsu Atom Bioscience and Pharmaceutical
• Arthrosi Therapeutics
• Teijin Limited
• Selecta Biosciences, Inc.
• Shanton Pharma

Learn more about the recent developments and breakthroughs in the Chronic Gout market @ Chronic Gout Clinical Trials

Chronic Gout Market Dynamics
As gout incidence and prevalence have risen dramatically in recent decades, the Chronic Gout market growth is shifting positively. Gout treatment in patients with concomitant metabolic syndrome and comorbid conditions such as renal impairment was previously difficult due to a lack of therapeutic options in the Chronic Gout market. However, with the introduction of new drugs for Chronic Gout, such as febuxostat and pegloticase, significant progress has been made in recent years. Many other drugs with rational mechanisms of action are in development and will most likely be launched in the Chronic Gout market in the coming years.

Certain factors, however, are impeding the growth of the Chronic Gout market. Both patients and doctors have a general lack of knowledge and understanding about gout care. Although gout is treatable, a lack of knowledge leads to underdiagnosis and undertreatment, particularly in people who do not fit the’stereotypical gout’ profile (for example, younger patients).

Scope of the Chronic Gout Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, Japan]
Key Chronic Gout Companies: Teijin Pharma, Horizon Therapeutics, Sanwa Kagaku Kenkyusho Co. Ltd., Jiangsu Atom Bioscience and Pharmaceutical, Arthrosi Therapeutics, Teijin Limited, Selecta Biosciences, Inc., Shanton Pharma, and others
Key Chronic Gout Pipeline Therapies: ABP 671, AR-882, TMX-049, Pegadricase-SVP, SAP 001, and others
Therapeutic Assessment: Chronic Gout current marketed and emerging therapies
Chronic Gout Market Dynamics: Chronic Gout market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Chronic Gout Market Access and Reimbursement

Table of Contents
1. Chronic Gout Market Key Insights
2. Chronic Gout Market Report Introduction
3. Chronic Gout Market Overview at a Glance
4. Chronic Gout Market Executive Summary
5. Disease Background and Overview
6. Chronic Gout Treatment and Management
7. Chronic Gout Epidemiology and Patient Population
8. Patient Journey
9. Chronic Gout Emerging Drugs
10. 7MM Chronic Gout Market Analysis
11. Chronic Gout Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Chronic Gout Market Drivers
15. Chronic Gout Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187